Evidence map›Paper›PMID 33027124›Full record

ArticleThe Journal of bone and joint surgery. American volume2020

Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas: An International Multicenter Study of 318 Cases.

E M Schutgens, P Picci, D Baumhoer, R Pollock, J V M G Bovée, P C W Hogendoorn, P D S Dijkstra, A J Rueten-Budde, P C Jutte, F Traub and 19 more

Abstract readMulticenter Study
In one paragraph

Article in The Journal of bone and joint surgery. American volume, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Review
  3. [Primary malignant bone tumours-part II].Radiologie (Heidelberg, Germany) · 2026
    Review
  4. Treatment and Management of Osteofibrous Dysplasia Like Adamantinoma - A Single Institution Experience.Journal of the Pediatric Orthopaedic Society of North America · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Adamantinoma: A SEER-based Epidemiological Analysis.Indian journal of surgical oncology · 2024
    Article
  10. Osteofibrous dysplasia: a narrative review.Journal of orthopaedic surgery and research · 2024
    Review
  11. Review
  12. Review
  13. [Primary malignant bone tumors].Orthopadie (Heidelberg, Germany) · 2023
    Article
  14. Article
  15. Article
  16. Recurrent Adamantinoma With Fibrous Dysplasia-like Feature.Clinical pathology (Thousand Oaks, Ventura County, Calif.)
    Article
  17. Adamantinoma: An Updated Review.In vivo (Athens, Greece)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

E M SchutgensDepartments of Orthopedic Surgery (E.M.S., P.D.S.D., and M.A.J.v.d.S.), Histopathology (J.V.M.G.B.), and Pathology (P.C.W.H.), Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0003-1435-2560
P PicciMedical Oncology, Musculoskeletal Oncology Department, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.ORCID 0000-0002-8519-4101
D BaumhoerBone Tumour Reference Centre, Institute of Pathology, University Hospital and University of Basel, Basel, Switzerland.ORCID 0000-0002-2137-7507
R PollockLondon Sarcoma Service, Royal National Orthopaedic Hospital, Stanmore, United Kingdom.ORCID 0000-0001-5227-9136
J V M G BovéeDepartments of Orthopedic Surgery (E.M.S., P.D.S.D., and M.A.J.v.d.S.), Histopathology (J.V.M.G.B.), and Pathology (P.C.W.H.), Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0003-1155-0481
P C W HogendoornDepartments of Orthopedic Surgery (E.M.S., P.D.S.D., and M.A.J.v.d.S.), Histopathology (J.V.M.G.B.), and Pathology (P.C.W.H.), Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-1513-8104
P D S DijkstraDepartments of Orthopedic Surgery (E.M.S., P.D.S.D., and M.A.J.v.d.S.), Histopathology (J.V.M.G.B.), and Pathology (P.C.W.H.), Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0001-5368-757
A J Rueten-BuddeMathematical Institute, Leiden University, Leiden, the Netherlands.ORCID 0000-0001-9627-8565
P C JutteDepartment of Orthopedics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID 0000-0002-6022-2807
F TraubOrthopedic Surgery, University of Tübingen, Tübingen, Germany.ORCID 0000-0002-6400-3257
A LeithnerDepartment of Orthopedics and Trauma, Medical University of Graz, Graz, Austria.ORCID 0000-0002-2598-2325
P-U TunnOrthopedic Surgery, Helios-Clinics, Berlin, Germany.ORCID 0000-0003-4837-5525
P FunovicsOrthopedic Surgery, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-9662-5942
G SysOrthopedic Surgery, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0002-5308-7846
M San-JulianOrthopedic Surgery, University of Navarra, Pamplona, Spain.ORCID 0000-0001-5502-506
G R SchaapOrthopedic Surgery, Academic Medical Center, Amsterdam, the Netherlands.ORCID 0000-0001-9687-165
H R DürrDepartment of Tumor Orthopedics and Sarcoma Surgery, University Hospital Essen, Essen, Germany.ORCID 0000-0001-5787-3994
J HardesMusculoskeletal Oncology, Department of Orthopedic Surgery, Physical Medicine and Rehabilitation, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0002-8408-2255
J HealeyOrthopedic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-0802-1186
R CapannaDepartment of Orthopaedics, S. Chiara University Hospital, University of Pisa, Italy.ORCID 0000-0003-4052-4880
D BiauOrthopedic Surgery, Cochin Hospital, Paris, France.ORCID 0000-0001-5953-462
A Gomez-BrouchetDepartment of Histopathology, University Medical Center, Toulouse, France.ORCID 0000-0003-1223-8393
J WunderUniversity Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada.ORCID 0000-0002-5978-9400
T D A CoskerOrthopedic Surgery, Nuffield Orthopedic Center, Oxford, United Kingdom.ORCID 0000-0001-9505-7955
M K LaitinenOrthopedic Surgery, Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0002-9975-0121
X NiuDepartment of Orthopedic Oncology, Beijing Jishuitan Hospital, Beijing, People's Republic of China.ORCID 0000-0001-7782-6669
V KostiukOrthopedic Surgery, National Cancer Institute Ukraine, Kiev, Ukraine.ORCID 0000-0003-2619-159
M A J van de SandeDepartments of Orthopedic Surgery (E.M.S., P.D.S.D., and M.A.J.v.d.S.), Histopathology (J.V.M.G.B.), and Pathology (P.C.W.H.), Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-9156-7656
Adamantinoma Research Group

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundOsteofibrous dysplasia-like adamantinoma (OFD-AD) and classic adamantinoma (AD) are rare, neoplastic diseases with only limited data supporting current treatment protocols. We believe that our retrospective multicenter cohort study is the largest analysis of patients with adamantinoma to date. The primary purpose of this study was to describe the disease characteristics and evaluate the oncological outcomes. The secondary purpose was to identify risk factors for local recurrence after surgical treatment and propose treatment guidelines.

methodsThree hundred and eighteen confirmed cases of OFD-AD and AD for which primary treatment was carried out between 1985 and 2015 were submitted by 22 tertiary bone tumor centers. Proposed clinical risk factors for local recurrence such as size, type, and margins were analyzed using univariable and multivariate Cox regression analysis.

resultsOf the 318 cases, 128 were OFD-AD and 190 were AD. The mean age at diagnosis was 17 years (median, 14.5 years) for OFD-AD and 32 years (median, 28 years) for AD; 53% of the patients were female. The mean tumor size in the OFD-AD and AD groups combined was 7.8 cm, measured histologically. Sixteen percent of the patients sustained a pathological fracture prior to treatment. Local recurrence was recorded in 22% of the OFD-AD cases and 24% of the AD cases. None of the recurrences in the OFD-AD group progressed to AD. Metastatic disease was found in 18% of the AD cases and fatal disease, in 11% of the AD cases. No metastatic or fatal disease was reported in the OFD-AD group. Multivariate Cox regression analysis demonstrated that uncontaminated resection margins (hazard ratio [HR] = 0.164, 95% confidence interval [CI] = 0.092 to 0.290, p < 0.001), pathological fracture (HR = 1.968, 95% CI = 1.076 to 3.600, p = 0.028), and sex (female versus male: HR = 0.535, 95% CI = 0.300 to 0.952, p = 0.033) impacted the risk of local recurrence.

conclusionsOFD-AD and AD are parts of a disease spectrum but should be regarded as different entities. Our results support reclassification of OFD-AD into the intermediate locally aggressive category, based on the local recurrence rate of 22% and absence of metastases. In our study, metastatic disease was restricted to the AD group (an 18% rate). We advocate wide resection with uncontaminated margins including bone and involved periosteum for both OFD-AD and AD. LEVEL OF EVIDENCE: Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.

Indexed as

AdamantinomaAdolescentAdultBone Diseases, DevelopmentalBone NeoplasmsFemaleHumansMaleNeoplasm Recurrence, LocalPrognosisRisk FactorsTreatment Outcome

Identifiers

PMID33027124
PMCPMC8569856

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.